Abstract

Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of autoimmune originate. The main agents responsible for the MS development include exogenous, environmental, and genetic factors. MS is characterized by multifocal and temporally scattered central nervous system (CNS) damage which lead to the axonal damage. Among clinical courses of MS it can be distinguish relapsing-remitting multiple sclerosis (RRMS), secondary progressive multiple sclerosis (SPSM), primary progressive multiple sclerosis (PPMS), and progressive-relapsing multiple sclerosis (RPMS). Depending on the severity of signs and symptoms MS can be described as benign MS or malignant MS. MS diagnosis is based on McDonald’s diagnostic criteria, which link clinical manifestation with characteristic lesions demonstrated by magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) analysis, and visual evoked potentials. Among CSF laboratory tests used to the MS diagnosis are applied: Tibbling & Link IgG index, reinbegrams, and CSF isoelectrofocusing for oligoclonal bands detection. It should be emphasized, that despite huge progress regarding MS as well as the availability of differentdiagnostics methods this disease is still a diagnostic challenge. It may result from fact that MS has diverse clinical course and there is a lack of single test, which would be of appropriate diagnostic sensitivity and specificity for quick and accurate diagnosis.

References

• 1. Amato M.P., Ponziani G., Bartolozzi M.L., Siracusa G.: A prospective study on the natural history of multiple sclerosis: clues to the conduct and interpretation of clinical trials. J. Neurol. Sci., 1999; 168: 96106
  Google Scholar
• 2. Andersson M., Alvarez-Cermeño J., Bernardi G., Cogato I., Fredman P., Fredriksen J., Fredrikson S., Gallo P., Grimaldi L.M., Grønning M.: Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. J. Neurol. Neurosurg. Psychiatry., 1994; 57: 897-902
  Google Scholar
• 3. Ascherio A., Munger K.L.: Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann. Neurol., 2007; 61: 288-299
  Google Scholar
• 4. Bailey P.: Incidence of multiple sclerosis in United States troops. Arch. Neurol. Psychiatry, 1922; 7: 582- 583
  Google Scholar
• 5. Barkhof F., Filippi M., Miller DH., Scheltens P., Campi A., Polman C.H., Comi G., Adèr H.J., Losseff N., Valk J.: Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain., 1997; 120: 20592069
  Google Scholar
• 6. Berger T., Rubner P., Schautzer F., Egg R., Ulmer H, Mayringer I., Dilitz E., Deisenhammer F., Reindl M.: Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N. Engl. J. Med., 2003; 349: 139145
  Google Scholar
• 7. Bonek R., Maciejek Z.: Naturalny przebieg stwardnienia rozsianego. Aktualności Neurol., 2009; 9: 116125
  Google Scholar
• 8. Bradburn J., Broughton S., Chadwick D., Royal College of Physicians of London: Multiple sclerosis. National clinical guideline for diagnosis and management in primary and secondary care. 2004; 8: 39-46
  Google Scholar
• 9. Brola W., Fudala M., Flaga S., Ryglewicz D.: O potrzebie stworzenia polskiego rejestru chorych na stwardnienie rozsiane. Neuro. Neurochir. Pol., 2013; 47: 484-492
  Google Scholar
• 10. Cendrowski W.: Survival in multiple sclerosis. Mult. Scler., 1998;4: 369370
  Google Scholar
• 11. Davenport C.B.: Multiple sclerosis: from the standpoint of geographicdistribution and race. Arch. Neurol. Psychiatry, 1922; 8: 51- 58
  Google Scholar
• 12. Davidson A.W, Scott R.F., Mitchell K.W.: The effect of contrastreduction on pattern-reversal VEPs in suspected multiple sclerosisand optic neuritis. Doc. Ophtalmol., 2004; 109: 157-161
  Google Scholar
• 13. Delpech B., Lichtblau E.: Immunochemical estimation of IgGand albumin in cerebrospinal fluid. Clin. Chim. Acta, 1972; 37: 15-23
  Google Scholar
• 14. Duddy M., Bar-Or A.: B-cells in multiple sclerosis. Int. MS J.,2006; 13: 8490
  Google Scholar
• 15. Dyment D.A., Ebers G.C., Sadovnick A.D.: Genetics of multiplesclerosis. Lancet. Neurol., 2004; 3: 104110
  Google Scholar
• 16. Ebers G.C.: Prognostic factors for multiple sclerosis: the importanceof natural history studies. J. Neurol., 2005; 252: iii15iii20
  Google Scholar
• 17. Ebers M.: Natural history of multiple sclerosis. W: Compston A.(red.) Mc Alpine’s Multiple Sclerosis, New York, Churchill Livingstone,1998, 191-221
  Google Scholar
• 18. Foote A.K., Blakemore W.F.: Inflammation stimulates remyelinationin areas of chronic demyelination. Brain., 2005; 128: 528539
  Google Scholar
• 19. Freal J.E., Kraft G.H., Coryell J.K.: Symptomatic fatigue in multiplesclerosis. Arch. Phys. Med. Rehabil., 1984; 65: 135-138
  Google Scholar
• 20. Frederiksen J.L., Larsson H.B., Olesen J., Stigsby B.: MRI, VEP, SEPand biothesiometry suggest monosymptomatic acute optic neuritisto be a first manifestation of multiple sclerosis. Acta. Neurol. Scand.,1991; 83: 343350
  Google Scholar
• 21. Freedman M.S., Thompson E.J., Deisenhammer F., GiovannoniG., Grimsley G., Keir G., Ohman S., Racke M.K., Sharief M., Sindic C.J.,Sellebjerg F., Tourtellotte W.W.: Recommended standard of cerebrospinal fluid analysis in the diagnosis of multiple sclerosis: a consensus statement. Arch. Neurol., 2005; 62: 865-870
  Google Scholar
• 22. Giorgio A., Stromillo M.L., Rossi F., Battaglini M., Hakiki B., PortaccioE., Federico A., Amato M.P., De Stefano N.: Cortical lesions inradiologically isolated syndrome. Neurology, 2011; 77: 1896-1899
  Google Scholar
• 23. Hartung H.P., Bar-Or A., Zoukos Y.: What do we know aboutthe mechanism of action of disease modifying treatments in MS? J.Neurol., 2004, 251: V12-V29
  Google Scholar
• 24. Henderson A.P., Barnett M.H., Parratt J.D., Prineas J.W.: Multiplesclerosis: distribution of inflammatory cells in newly forminglesions. Ann. Neurol., 2009; 66: 739-753
  Google Scholar
• 25. Honig L.S., Sheremata W.A.: Magnetic resonance imaging ofspinal cord lesions in multiple sclerosis. J. Neurol. Neurosurg. Psychiatry,1989; 52: 459-466
  Google Scholar
• 26. Jurewicz A.: Badanie płynu mózgowo-rdzeniowego w stwardnieniurozsianym. Pol. Przegl. Neurol., 2005, 1: 114-117
  Google Scholar
• 27. Kantarci O.H., Weinshenker B.G.: Natural history of multiplesclerosis. Neurol. Clin., 2005; 23: 1738
  Google Scholar
• 28. Kostulas V.K., Link H., Lefvert A.K.: Oligoclonal IgG bands incerebrospinal fluid. Principles for demonstration and interpretationbased on findings in 1114 neurological patients. Arch. Neurol.,1987; 44: 10411044
  Google Scholar
• 29. Kułakowska A., Mroczko B., Mantur M., Lelental N., Tarasiuk J.,Kapica-Topczewska K., Schulz U., Lange P., Zimmermann R., KornhuberJ., Lewczuk P.: Multiplexing analysis of the polyspecific intrathecalimmune response in multiple sclerosis. Methods., 2012; 56: 528-531
  Google Scholar
• 30. Lampasona V., Franciotta D., Furlan R., Zanaboni S., Fazio R., BonifacioE., Comi G., Martino G.: Similar low frequency of anti-MOG IgGand IgM patients and healthy subjects. Neurology, 2004; 62: 20922094
  Google Scholar
• 31. Lassmann H., Brück W., Lucchinetti C.F.: The immunopathologyof multiple sclerosis: an overview. Brain Pathol., 2007; 17: 210218
  Google Scholar
• 32. Lewczuk P., Mantur M.: Płyn mózgowo rdzeniowy. Badanie i interpretacjawyników. Wydawnictwo Ekonomia i Środowisko. Bia-łystok, 2002
  Google Scholar
• 33. Link H., Huang Y.M.: Oligoclonal bands in multiple sclerosis cerebrospinalfluid: an update on methodology and clinical usefulness.J. Neuroimmunol., 2006; 180: 1728
  Google Scholar
• 34. Lublin F.D.: Clinical features and diagnosis of multiple sclerosis.Neurol. Clin., 2005; 23: 115
  Google Scholar
• 35. Lublin F.D., Reingold S.C.: Defining the clinical course of multiplesclerosis: results of an international survey. National MultipleSclerosis Society (USA) Advisory Committee on Clinical Trials of NewAgents in Multiple Sclerosis. Neurology, 1996; 46: 907911
  Google Scholar
• 36. Lublin F.D., Reingold S.C., Cohen J.A., Cutter G.R., Sørensen P.S.,Thompson A.J., Wolinsky J.S., Balcer L.J., Banwell B., Barkhof F., BeboB. Jr., Calabresi P.A., Clanet M., Comi G., Fox R.J. i wsp.: Defining theclinical course of multiple sclerosis: the 2013 revisions. Neurology,2014; 83: 278-286
  Google Scholar
• 37. Lucchinetti C., Brück W., Parisi J., Scheithauer B., Rodriguez M.,Lassmann H.: Heterogeneity of multiple sclerosis lesions: implicationsfor the pathogenesis of demyelination. Ann. Neurol., 2000;47: 707-717
  Google Scholar
• 38. Maciejek Z.: Diagnostyka stwardnienia rozsianego. Farmako.Psych. Neurol., 2005; 3: 209-217
  Google Scholar
• 39. Marik C., Felts P.A., Bauer J., Lassmann H., Smith K.J.: Lesion genesisin a subset of patients with multiple sclerosis: a role for innateimmunity? Brain, 2007; 130: 2800-2815
  Google Scholar
• 40. Marrie R.A.: Environmental risk factors in multiple sclerosisaetiology. Lancet Neurol., 2004; 3: 709-718
  Google Scholar
• 41. McDonald W.I., Compston A., Edan G., Goodkin D., Hartung H.P.,Lublin F.D., McFarland H.F., Paty D.W., Polman C.H., Reingold S.C.,Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S.,Weinshenker B.Y., Wolinsky J.S.: Recommended diagnostics criteriafor multiple sclerosis: guidelines from the International Panel onthe diagnosis of multiple sclerosis. Ann. Neurol., 2001; 50: 121-127
  Google Scholar
• 42. Miller D., Barkhof F., Montalban X., Thompson A., Filippi M.:Clinically isolated syndromes suggestive of multiple sclerosis, partI: natural history, pathogenesis, diagnosis, and prognosis. LancetNeurol., 2005; 4: 281-288
  Google Scholar
• 43. Miller D.H., Barkhof F., Nauta J.J.: Gadolinium enhancement increasesthe sensitivity of MRI in detecting disease activity in multiplesclerosis. Brain, 1993; 116: 10771094
  Google Scholar
• 44. Miller D.H., Hornabrook R.W., Purdie G.: The natural history ofmultiple sclerosis: a regional study with some longitudinal data. J.Neurol. Neurosurg. Psychiatry, 1992; 55: 341346
  Google Scholar
• 45. Morrissey S.P., Miller D.H., Kendall B.E., Kingsley D.P., KellyM.A., Francis D.A., MacManus D.G., McDonald W.I.: The significanceof brain magnetic resonance imaging abnormalities at presentationwith clinically isolated syndromes suggestive of multiple sclerosis.A 5 year follow up study. Brain, 1993; 116: 135146
  Google Scholar
• 46. Noseworthy J.H., Lucchinetti C., Rodriguez M., Weinshenker B.G.:Multiple sclerosis. N. Engl. J. Med., 2000; 343: 938-952
  Google Scholar
• 47. Okuda D.T., Mowry E.M., Beheshtian A., Waubant E., BaranziniS.E., Goodin D.S., Hauser S.L., Pelletier D.: Incidental MRI anomaliessuggestive of multiple sclerosis: the radiologically isolated syndrome.Neurology, 2009; 72: 800-805
  Google Scholar
• 48. Okuda D.T., Mowry E.M., Cree B.A., Crabtree E.C., Goodin D.S.,Waubant E., Pelletier D.: Asymptomatic spinal cord lesions predictdisease progression in radiologically isolated syndrome. Neurology,2011; 76: 686-692
  Google Scholar
• 49. Polman C.H., Reingold S.C., Banwell B., Clanet M., Cohen J.A.,Filippi M., Fujihara K., Havrdova E., Hutchinson M., Kappos L., LublinF.D., Montalban X., O’Connor P., Sandberg-Wollheim M., ThompsonA.J. i wsp.: Diagnostic criteria for multiple sclerosis: 2010 revisionsto the McDonald criteria. Ann. Neurol., 2011; 69: 292-302
  Google Scholar
• 50. Polman C.H., Reingold S.C., Edan G., Filippi M., Hartung H.P.,Kappos L., Lublin F.D., Metz L.M., McFarland H.F., O’Connor P.W.,Sandberg-Wollheim M., Thompson A.J., Weinshenker B.G., WolinskyJ.S.: Diagnostic criteria for multiple sclerosis: 2005 revisions to the”McDonald Criteria’’. Ann. Neurol., 2005; 58: 840-846
  Google Scholar
• 51. Poser C.M.: The dissemination of multiple sclerosis: a Vikingsaga? A historical essay. Ann. Neurol., 1994; 36: S231-S 243
  Google Scholar
• 52. Potemkowski A.: Stwardnienie rozsiane w świecie i w Polsce -ocena epidemiologiczna. Aktualności Neurol., 2009; 9: 91-97
  Google Scholar
• 53. Pugliatti M., Riise T., Sotgiu M.A., Sotgiu S., Satta W.M., MannuL., Sanna G., Rosati G.: Increasing incidence of multiple sclerosisin the province of Sassari, northern Sardinia. Neuroepidemiology,2005; 25: 129134
  Google Scholar
• 54. Pugliatti M., Rosati G., Carton H., Riise T., Drulovic J., Vécsei L.,Milanov I.: The epidemiology of multiple sclerosis in Europe. Eur. J.Neurol., 2006; 13: 700-722
  Google Scholar
• 55. Ramagopalan S.V., Dobson R., Meier U.C., Giovannoni G.: Multiplesclerosis: Risk factors, prodromes, and potential causal pathways.Lancet Neurol., 2010; 9: 727-739
  Google Scholar
• 56. Reiber H.: Flow rate of cerebrospinal fluid (CSF) – a conceptcommon to normal blond-CSF barrier function and to dysfunctionin neurological diseases. J. Neurol. Sci., 1994; 122: 189-203
  Google Scholar
• 57. Reiber H.: Cerebrospinal fluid – physiology, analysis and interpretationof protein patterns for diagnosis of neurological diseases. Mult. Scler., 1998; 4: 99-107
  Google Scholar
• 58. Reiber H., Lange P.: Quantification of virus-specific antibodiesin cerebrospinal fluid and serum: sensitive and specific detection ofantibody synthesis in brain. Clin. Chem., 1991; 37: 1153-1160
  Google Scholar
• 59. Rieckmann P., Toyka K.V., Bassetti C., Beer K., Beer S., BuettnerU., Chofflon M., Götschi-Fuchs M., Hess K., Kappos L., Kesselring J.,Goebels N., Ludin H.P., Mattle H., Schluep M. i wsp.: Escalating immunotherapyof multiple sclerosis. New aspects and practical application.J. Neurol., 2004; 251: 1329-1339
  Google Scholar
• 60. Rosati G.: The prevalence of multiple sclerosis in the world: anupdate. Neurol. Sci., 2001; 22: 117-139
  Google Scholar
• 61. Runmarker B., Andersen O.: Prognostic factors in a multiplesclerosis incidence cohort with twenty five years of follow up. Brain,1993; 116: 117134
  Google Scholar
• 62. Sadovnick A.D.: Genetic epidemiology of multiple sclerosis: a survey.Ann. Neurol., 1994; 36: S194S203
  Google Scholar
• 63. Sadovnick A.D, Baird P.A., Ward R.H.: Multiple sclerosis: updatedrisks for relatives. Am. J. Med. Genet., 1988; 29: 533541
  Google Scholar
• 64. Sadovnick A.D., Ebers G.C.: Epidemiology of multiple sclerosis:a critical overview. Canad. J. Neurol. Sci., 1993; 20: 17-29
  Google Scholar
• 65. Sawcer S., Hellenthal G., Pirinen M., Spencer C.C., PatsopoulosN.A., Moutsianas L., Dilthey A., Su Z., Freeman C., Hunt S.E., EdkinsS., Gray E., Booth D.R., Potter S.C., Goris A., i wsp.: Genetic risk anda primary role for cell-mediated immune mechanisms in multiplesclerosis. Nature, 2011; 476: 214-219
  Google Scholar
• 66. Selmaj K.: Stwardnienie rozsiane – kryteria diagnostyczne i naturalnyprzebieg choroby. Pol. Przegl. Neurol., 2005; 1: 99-105
  Google Scholar
• 67. Shaw C., Chapman C., Butzkueven H.: How to diagnose multiplesclerosis and what are the pitfalls. Intern. Med. J., 2009; 39: 792-799
  Google Scholar
• 68. Siger M.: Diagnostyka laboratoryjna stwardnienia rozsianego.Aktualn. Neurol., 2009; 9: 101108
  Google Scholar
• 69. Smolders J., Damoiseaux J., Menheere P., Hupperts R.: VitaminD as an immune modulator in multiple sclerosis: a review. J. Neuroimmunol.,2008; 194: 7-17
  Google Scholar
• 70. Stuart W.H.: Clinical management of multiple sclerosis: the treatmentparadigm and issues of patient management. J. Manag. Care.Pharm., 2004, 10: S19-S25
  Google Scholar
• 71. Tibbling G., Link H., Ohman S.: Principles of albumin and IgGanalyses in neurological disorders. I. Establishment of referencevalues. Scand. J. Clin. Lab. Invest., 1977; 37: 385-390
  Google Scholar
• 72. Tintoré M., Rovira A., Martínez M.J., Rio J., Díaz-Villoslada P.,Brieva L., Borrás C., Grivé E., Capellades J., Montalban X.: Isolateddemyelinating syndromes: comparison of different MRI imaging criteriato predict conversion to clinically definite multiple sclerosis.Am. J. Neuroradiol., 2000; 21: 702706
  Google Scholar
• 73. Tourtellotte W.W., Baumhefner R.W., Syndulko K., Shapshak P.,Osborne M., Rubinshtein G., Newton L., Ellison G., Myers L., RosarioI.: The long march of the cerebrospinal fluid profile indicative ofclinical definite multiple sclerosis; and still marching. J. Neuroimmunol.,1988; 20: 217227
  Google Scholar
• 74. Trapp B.D., Peterson J., Ransohoff R.M., Rudick R., Mörk S., BöL.: Axonal transection in the lesions of multiple sclerosis. N. Engl. J.Med., 1998; 338: 278-285
  Google Scholar
• 75. Tur C., Montalban X.: CSF oligoclonal bands are important inthe diagnosis of multiple sclerosis, unreasonably downplayed by theMcDonald Criteria 2010: No. Mult. Scler., 2013; 19: 717-718
  Google Scholar
• 76. Zwibel H.L., Smrtka J.: Improving quality of life in multiplesclerosis: an unmet need. Am. J. Manag. Care, 2011;17: S139-S145
  Google Scholar

Full text